March 07, 2005 13:46 ET

Insulin Abnormalities Linked to Alzheimer's Disease by Researchers; Nymox AD Protein Marker -NTP- Is Linked to Impaired Insulin Function and Accelerated Brain Cell Death




MARCH 7, 2005 - 13:46 ET

Insulin Abnormalities Linked to Alzheimer's Disease by
Researchers; Nymox AD Protein Marker -NTP- Is Linked
to Impaired Insulin Function and Accelerated Brain
Cell Death

MAYWOOD, N.J.--(CCNMatthews - Mar 7, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that a
research team led by Dr Suzanne de la Monte and Dr. Jack Wands of the
Brown University Medical School has found evidence that impaired insulin
functioning may be behind the diverse constellation of abnormalities
found in Alzheimer's disease. The findings were published in the latest
issue of Journal of Alzheimer's Disease (2005; 7(1): 63-80).

In an accompanying review article on the links between insulin and
Alzheimer's disease, the authors note that abnormalities in gene
expression that result in impaired insulin function in the brain,
including those reported with respect to neural thread protein (NTP),
may play important roles in precipitating the cascade of
neurodegeneration found in AD (Journal of Alzheimer's Disease (2005;
7(1): 45-61)). The Brown research team has already linked neural thread
protein (NTP), the brain protein measured by the company's proprietary
urine AlzheimAlert™ test, to impaired insulin functioning and
accelerated death in brain cells (Journal of Alzheimer's Disease 2004;
6(3): 231-42).

Nymox is developing new generation drugs that target NTP and the harmful
role it plays in the Alzheimer's disease process. Previous published
studies spanning over a decade of research found that NTP is elevated in
the brain tissue, cerebrospinal fluid and urine of Alzheimer's disease
patients and demonstrated that increased NTP production is associated
with many of the characteristic signs of cell death and changes found in
Alzheimer's disease.

The Company currently offers AlzheimAlert™, a non-invasive urine test
which measures the level of NTP in patients suspected of having
Alzheimer's disease, its CLIA certified reference laboratory in Maywood
NJ. The test provides physicians with a valuable tool for the diagnosis
of Alzheimer's disease.

Nymox has also developed a kit version of its AlzheimAlert™
technology. The new AlzheimAlert™ test kit is certified with a CE
Mark, making the device eligible for sale in the European Union. The
Company recently announced the signing of an agreement with Alifax
s.P.a. to distribute the kit to laboratories and hospitals in Italy.

According to a recent study (Arch Neurol 2003; 60: 1119-1122), there are
4.5 million people with Alzheimer's disease in the United States alone;
by 2050 this number is projected to increase almost three times to 13.2
million. Worldwide estimates of the current number of people with
Alzheimer's disease range from 15 to 20 million. The annual national
direct and indirect costs of caring for Alzheimer patients in the U.S.
alone is estimated at $100 billion. The human toll on patients, families
and caregivers is incalculable.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in
the research and development of therapeutics and diagnostics, with a
particular emphasis on products targeted for the unmet needs of the
aging population. Currently Nymox has three products on the market, and
a healthy pipeline of drug and diagnostic products. The Company also has
several hundred patents and patent applications. The Company is
conducting pivotal Phase II clinical trials for NX-1207, a new drug for
benign prostatic hyperplasia (BPH). The Company markets NicAlert™ and
TobacAlert™ tests for measuring tobacco product exposure. Nymox has a
number of other drugs in development for Alzheimer's disease, oncology,
and infectious disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.


Contact Information

    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX